Dr. Jason Jerry Among Recipients of National Honor for Anti-Opioid Efforts

U.S. AG’s Award recognizes model now being replicated nationwide

16-neu-2604-doj-650×450
jason-jerry

Jason Jerry, MD

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Members of the U.S. Attorney’s Northeast Ohio Heroin and Opioid Task Force — including Cleveland Clinic addiction psychiatrist Jason Jerry, MD — have been granted the U.S. Attorney General’s Award, the most prestigious honor given by the federal Department of Justice, for their work combating opioid addiction in greater Cleveland.

They accepted the award in Washington, D.C., on Nov. 10 from Attorney General Loretta Lynch, fifth from the left in the photo above (Dr. Jerry is next to her, sixth from the left).

Recognizing the ‘Cleveland Model’

Dr. Jerry, a specialist in addiction and recovery, has been involved with the Northeast Ohio Heroin and Opioid Task Force since its formation in 2013 to address the region’s significant opioid addiction epidemic. His roles have included service as chairman of its treatment subcommittee.

Advertisement

The task force focuses on solutions to the epidemic from four perspectives — law enforcement, education and prevention, healthcare policy, and treatment. Task force members include law enforcement officials, physicians and other treatment professionals, people in recovery, judges, public health professionals, educators and others.

“It’s great to see the task force be recognized for all the hard work that’s been devoted to this effort,” says Dr. Jerry. “We still have a long way to go, but our work thus far is important and is being replicated by other U.S. Attorney’s offices around the country. We understand the model of our task force is being called the ‘Cleveland Model’.”

Combating addiction on multiple fronts

The award — known in full as the U.S. Attorney General’s Award for Outstanding Community Partnerships for Public Safety — recognizes achievement in the development and support of community partnerships designed to address public safety within a community.

Advertisement

Specific accomplishments of the Northeast Ohio Heroin and Opioid Task Force that contributed to the recognition include:

  • Efforts to make naloxone more readily available throughout the region
  • Presentations to tens of thousands of parents, students and other community members at hundreds of town hall meetings and schools
  • Increased training for physicians and other health providers about the dangers of opioids
  • Creation of a heroin-involved death investigation team that treats sites of overdoses as crime scenes to support enhanced criminal charges for dealers when appropriate
  • Work to increase the availability of drug treatment for addiction

“It is easy to become discouraged about the wave of death and pain that opioids and heroin bring to our community,” says U.S. Attorney Carole Rendon, who chairs the task force. “But I know the incredible efforts of all the members of this team make a difference on a daily basis. This approach has become a national model.”

Related Articles

23-NEU-3516858-brain-trauma-650×450
Neurotrauma Guidelines: Where They’ve Been, Where They’re Headed and How to Make the Most of Them

Q&A with Brain Trauma Foundation guideline architect Gregory Hawryluk, MD, PhD

20-NEU-2020111 neuroimmunology_650x450
Autoimmune Neurologic Disorders: Treatable Conditions That Should Not Be Missed

Q&A with newly arrived autoimmune neurology specialist Amy Kunchok, MD

20-NEU-1984276 multimodal-monitoring_650x450
Multimodal Monitoring in the Neuro ICU: Essentials for Clinicians (Podcast)

A neurocritical care specialist shares what’s spurring growth of this new evaluation approach

central vein sign in multiple sclerosis
New Frontiers in Diagnosing and Monitoring Multiple Sclerosis (Podcast)

Get ready for central vein sign and optical coherence tomography

20-NEU-1938374-migraine_650x450
CGRP Antagonists for Decreasing Migraine Frequency: A Primer

How these new drugs fit into practice two years out from their first approvals

20-NEU-1892171 CQD_650x450_CCC-1901608_06-03-20_0443
What’s Afoot and What’s Ahead for Physical Medicine and Rehabilitation

A conversation on the state of physiatry with the AAPM&R’s Vice President

Ad